Ipsen to acquire Kartos Therapeutics in deal valued Up to $1.75 billion
PARIS: Ipsen and Kartos Therapeutics announced Monday they have entered into a definitive merger agreement under which Ipsen will acquire Kartos Therapeutics for $450 million upfront, with additional milestone payments of up to $1.3 billion. The acquisition adds navtemadlin, an investigational MDM2 inhibitor designed…